Sotatercept for the treatment of portopulmonary hypertension: a case report
Abstract
Background: Portopulmonary Hypertension is a subtype of pulmonary arterial hypertension with high mortality. There are extremely few clinical trials to guide treatment in portopulmonary hypertension, which is typically based on the approach to treatment for other types of pulmonary arterial hypertension. Sotatercept, the newest pulmonary arterial hypertension approved therapeutic, is a novel activin signaling inhibitor which has been shown to significantly improve disease severity and enhance survival when added to background therapy in pulmonary arterial hypertension. Unfortunately, portopulmonary hypertension patients were excluded from the clinical trials that led to Sotatercept approval, and the efficacy, safety, and tolerability of Sotatercept in portopulmonary hypertension remains unclear.
Methods: Here we describe, to the best of our knowledge, a case report of the first use of Sotatercept in the treatment of portopulmonary hypertension, combined with single cell RNA sequencing and plasma proteomic analysis.
Results: We demonstrate that profiling the circulating leukocyte transcriptomic and circulating pulmonary artery proteomic signatures before and after Sotatercept treatment identifies changes in CD8 + T-Cell and Monocyte gene expression, and levels of proteins involved in inflammation and ubiquitination. Sotatercept appears well tolerated, effective in reducing pulmonary hypertension hemodynamic severity in a portopulmonary hypertension patient refractory to…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.